Yan Jin

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Part of Hepagene Therapeutics, Inc., Yatra Pharmaceutical Technology (Shanghai) Co., Ltd. is a Chinese company that engages in research and development of new drugs. The company is based in Shanghai, China. The company was founded in 2016 by Xiao Dong Xu.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. Its product pipelines focus on the treatment of resistant Gram-positive and Gram-negative bacterial infections. The company was founded by Zheng Yu Yuan and Mikhail F. Gordeev on August 7, 2012 and is headquartered in Shanghai, China.